Product name

Summary

Organization name

Profile

Technology

Novel rhodium-based compounds with a strong cytostatic capability are offered for the therapy of cancer. Determination of IC50 values of the discovered rhodium complexes revealed a strong cytostatic effect in breast cancer cells and colon carcinoma cells.

The activity was up to 100fold higher compared to known cytostatica. The rhodium complexes exhibit a high potential in regard of the increasing resistences of tumors to common chemotherapeutic agents, such as Cisplatin or Carboplatin.

Thus the novel antitumor-active rhodium complexes represent powerful compounds to fight especially breast and colorectal cancer.  

Advantages

• Therapy of various kinds of cancer and metastases, especially breast and colorectal cancer
• No known resistence development of tumors to rhodium complexes
• Up to 100fold higher activity in comparison to cisplatin

European patent application filed.

This product candidates have been developed at the Freie Universität Berlin and the Ruhr-Universität Bochum, Germany and are offered by IPAL.

Contact

IPAL GmbH 
Dr. Andreas Voigt
andreas.voigt(at)ipal.de

About IPAL 

The ipal GmbH patent agency assesses and markets the inventions of scientists in the area of Life Sciences and Physics & Engineering from Charité-Universitätsmedizin (University Medicine), Robert Koch Institute, Deutsches Herzzentrum (German Heart Institute), Bundesanstalt für Materialprüfung (BAM - Federal Institute for Materials Research and Testing), the Zuse Institute as well as the Paul Ehrlich Institute, Langen and the Jacobs University Bremen. IPAL provides all of the services necessary - from the assessment of patentable technologies to a comprehensive patent protection all the way to the evaluation of sales returns potentials on the market and successful commercialisation through the use of licensing agreements.

Description File

URL

Your feedback

back